Translational Development Acquisition Corp. Ordinary Shares (TDAC) - Total Liabilities
Based on the latest financial reports, Translational Development Acquisition Corp. Ordinary Shares (TDAC) has total liabilities worth $6.46 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TDAC year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Translational Development Acquisition Corp. Ordinary Shares - Total Liabilities Trend (2022–2024)
This chart illustrates how Translational Development Acquisition Corp. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. See Translational Development Acquisition Co (TDAC) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Translational Development Acquisition Corp. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Translational Development Acquisition Corp. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Karel Elektronik Sanayi ve Ticaret AS
IS:KAREL
|
Turkey | TL10.98 Billion |
|
Triplepoint Venture Growth BDC Corp
NYSE:TPVG
|
USA | $456.11 Million |
|
Shenzhen Weiye Decoration Group Co Ltd
SHE:300621
|
China | CN¥13.51 Billion |
|
Delta Corp Limited
NSE:DELTACORP
|
India | Rs3.22 Billion |
|
Lithium Royalty Corp
TO:LIRC
|
Canada | CA$2.82 Million |
|
Intelligent Monitoring Group Ltd
AU:IMB
|
Australia | AU$157.42 Million |
|
Central Industrial Corp
KLSE:8052
|
Malaysia | RM321.14 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.22 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down Translational Development Acquisition Corp. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Translational Development Acquisition Co market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Translational Development Acquisition Corp. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Translational Development Acquisition Corp. Ordinary Shares (2022–2024)
The table below shows the annual total liabilities of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.25 Million | +1125.83% |
| 2023-12-31 | $509.68K | +10.96% |
| 2022-12-31 | $459.34K | -- |
About Translational Development Acquisition Corp. Ordinary Shares
Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.